Nephros, Inc. (NEPH)
USD 1.48
(-3.9%)
USD 1.48
(-3.9%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.86 Million USD | 7.84% |
| 2022 | 10.99 Million USD | -37.68% |
| 2021 | 17.65 Million USD | -4.65% |
| 2020 | 18.51 Million USD | 59.17% |
| 2019 | 11.62 Million USD | 10.14% |
| 2018 | 10.55 Million USD | 111.88% |
| 2017 | 4.98 Million USD | 86.07% |
| 2016 | 2.67 Million USD | -32.54% |
| 2015 | 3.97 Million USD | 17.84% |
| 2014 | 3.36 Million USD | 16.61% |
| 2013 | 2.88 Million USD | -18.11% |
| 2012 | 3.52 Million USD | -11.67% |
| 2011 | 3.99 Million USD | 151.19% |
| 2010 | 1.59 Million USD | -40.05% |
| 2009 | 2.65 Million USD | -34.29% |
| 2008 | 4.03 Million USD | -59.98% |
| 2007 | 10.08 Million USD | 95.19% |
| 2006 | 5.16 Million USD | -33.97% |
| 2005 | 7.82 Million USD | -35.9% |
| 2004 | 12.2 Million USD | 142.5% |
| 2003 | 5.03 Million USD | 293.4% |
| 2002 | 1.27 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 11.1 Million USD | -2.77% |
| 2024 Q1 | 11.41 Million USD | -3.75% |
| 2023 Q3 | 10.91 Million USD | 5.13% |
| 2023 Q2 | 10.38 Million USD | -4.95% |
| 2023 Q1 | 10.92 Million USD | -0.65% |
| 2023 FY | 11.86 Million USD | 7.84% |
| 2023 Q4 | 11.86 Million USD | 8.63% |
| 2022 Q1 | 15.52 Million USD | -12.02% |
| 2022 Q3 | 11.33 Million USD | -24.2% |
| 2022 Q4 | 10.99 Million USD | -2.96% |
| 2022 FY | 10.99 Million USD | -37.68% |
| 2022 Q2 | 14.95 Million USD | -3.7% |
| 2021 FY | 17.65 Million USD | -4.65% |
| 2021 Q2 | 17.99 Million USD | 0.31% |
| 2021 Q3 | 17.82 Million USD | -0.95% |
| 2021 Q4 | 17.65 Million USD | -0.95% |
| 2021 Q1 | 17.93 Million USD | -3.1% |
| 2020 Q3 | 15.24 Million USD | -8.45% |
| 2020 Q1 | 18.29 Million USD | 57.31% |
| 2020 Q2 | 16.64 Million USD | -8.99% |
| 2020 Q4 | 18.51 Million USD | 21.44% |
| 2020 FY | 18.51 Million USD | 59.17% |
| 2019 Q2 | 12.01 Million USD | 18.5% |
| 2019 FY | 11.62 Million USD | 10.14% |
| 2019 Q3 | 11.55 Million USD | -3.83% |
| 2019 Q4 | 11.62 Million USD | 0.65% |
| 2019 Q1 | 10.13 Million USD | -3.98% |
| 2018 Q1 | 4.63 Million USD | -7.04% |
| 2018 Q4 | 10.55 Million USD | 12.27% |
| 2018 FY | 10.55 Million USD | 111.88% |
| 2018 Q2 | 6.84 Million USD | 47.78% |
| 2018 Q3 | 9.4 Million USD | 37.38% |
| 2017 Q3 | 2.82 Million USD | -0.6% |
| 2017 Q2 | 2.84 Million USD | -13.36% |
| 2017 Q4 | 4.98 Million USD | 76.45% |
| 2017 FY | 4.98 Million USD | 86.07% |
| 2017 Q1 | 3.27 Million USD | 22.44% |
| 2016 Q1 | 3.42 Million USD | -13.68% |
| 2016 Q3 | 3.01 Million USD | -24.66% |
| 2016 Q2 | 3.99 Million USD | 16.57% |
| 2016 FY | 2.67 Million USD | -32.54% |
| 2016 Q4 | 2.67 Million USD | -11.03% |
| 2015 Q2 | 3.39 Million USD | 29.33% |
| 2015 FY | 3.97 Million USD | 17.84% |
| 2015 Q1 | 2.62 Million USD | -22.17% |
| 2015 Q4 | 3.97 Million USD | -7.78% |
| 2015 Q3 | 4.3 Million USD | 26.95% |
| 2014 Q4 | 3.36 Million USD | 8.5% |
| 2014 Q2 | 2.35 Million USD | -23.11% |
| 2014 Q1 | 3.05 Million USD | 5.88% |
| 2014 FY | 3.36 Million USD | 16.61% |
| 2014 Q3 | 3.1 Million USD | 32.02% |
| 2013 Q4 | 2.88 Million USD | 13.03% |
| 2013 Q3 | 2.55 Million USD | -11.31% |
| 2013 FY | 2.88 Million USD | -18.11% |
| 2013 Q2 | 2.88 Million USD | 5.3% |
| 2013 Q1 | 2.73 Million USD | -22.42% |
| 2012 Q2 | 4.34 Million USD | 20.84% |
| 2012 Q3 | 3.95 Million USD | -9.04% |
| 2012 Q4 | 3.52 Million USD | -10.82% |
| 2012 Q1 | 3.59 Million USD | -9.89% |
| 2012 FY | 3.52 Million USD | -11.67% |
| 2011 Q3 | 2.88 Million USD | 3.26% |
| 2011 Q1 | 3.64 Million USD | 129.5% |
| 2011 Q2 | 2.79 Million USD | -23.43% |
| 2011 FY | 3.99 Million USD | 151.19% |
| 2011 Q4 | 3.99 Million USD | 38.44% |
| 2010 Q2 | 1.94 Million USD | -15.16% |
| 2010 Q1 | 2.28 Million USD | -13.69% |
| 2010 FY | 1.59 Million USD | -40.05% |
| 2010 Q4 | 1.59 Million USD | -5.47% |
| 2010 Q3 | 1.68 Million USD | -13.39% |
| 2009 FY | 2.65 Million USD | -34.29% |
| 2009 Q3 | 3.27 Million USD | 40.13% |
| 2009 Q1 | 3.17 Million USD | -21.41% |
| 2009 Q2 | 2.34 Million USD | -26.23% |
| 2009 Q4 | 2.65 Million USD | -19.12% |
| 2008 FY | 4.03 Million USD | -59.98% |
| 2008 Q4 | 4.03 Million USD | -24.25% |
| 2008 Q3 | 5.32 Million USD | -27.54% |
| 2008 Q2 | 7.35 Million USD | -16.07% |
| 2008 Q1 | 8.76 Million USD | -13.13% |
| 2007 Q3 | 14.19 Million USD | 496.26% |
| 2007 Q4 | 10.08 Million USD | -28.93% |
| 2007 Q1 | 3.39 Million USD | -34.37% |
| 2007 Q2 | 2.38 Million USD | -29.81% |
| 2007 FY | 10.08 Million USD | 95.19% |
| 2006 Q3 | 7 Million USD | -21.17% |
| 2006 Q4 | 5.16 Million USD | -26.21% |
| 2006 FY | 5.16 Million USD | -33.97% |
| 2006 Q1 | 6.2 Million USD | -20.7% |
| 2006 Q2 | 8.88 Million USD | 43.17% |
| 2005 Q3 | 9.43 Million USD | -14.85% |
| 2005 Q2 | 11.08 Million USD | -13.83% |
| 2005 FY | 7.82 Million USD | -35.9% |
| 2005 Q1 | 12.86 Million USD | 5.37% |
| 2005 Q4 | 7.82 Million USD | -17.1% |
| 2004 Q4 | 12.2 Million USD | -20.84% |
| 2004 FY | 12.2 Million USD | 142.5% |
| 2004 Q2 | 6.26 Million USD | 0.0% |
| 2004 Q3 | 15.42 Million USD | 146.12% |
| 2003 FY | 5.03 Million USD | 293.4% |
| 2002 FY | 1.27 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 180.36 Million USD | 93.424% |
| AngioDynamics, Inc. | 317.67 Million USD | 96.266% |
| AtriCure, Inc. | 613.93 Million USD | 98.068% |
| Avinger, Inc. | 13.77 Million USD | 13.863% |
| Azenta, Inc. | 2.88 Billion USD | 99.589% |
| BioLife Solutions, Inc. | 412.71 Million USD | 97.126% |
| The Cooper Companies, Inc. | 11.65 Billion USD | 99.898% |
| Daxor Corporation | 34.86 Million USD | 65.984% |
| Ekso Bionics Holdings, Inc. | 28.91 Million USD | 58.984% |
| Femasys Inc. | 27.75 Million USD | 57.267% |
| GlucoTrack, Inc. | 4.9 Million USD | -141.814% |
| Harvard Bioscience, Inc. | 137.36 Million USD | 91.365% |
| Hologic, Inc. | 9.15 Billion USD | 99.87% |
| ICU Medical, Inc. | 4.37 Billion USD | 99.729% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 99.923% |
| KORU Medical Systems, Inc. | 28.46 Million USD | 58.325% |
| LeMaitre Vascular, Inc. | 346.77 Million USD | 96.58% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -90.729% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -90.729% |
| Masimo Corporation | 3.04 Billion USD | 99.61% |
| Microbot Medical Inc. | 8.32 Million USD | -42.44% |
| Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | 93.101% |
| Merit Medical Systems, Inc. | 2.32 Billion USD | 99.49% |
| NovoCure Limited | 1.14 Billion USD | 98.965% |
| NEXGEL, Inc. | 9.95 Million USD | -19.146% |
| NEXGEL, Inc. | 9.95 Million USD | -19.146% |
| Singular Genomics Systems, Inc. | 265.46 Million USD | 95.532% |
| OraSure Technologies, Inc. | 482.84 Million USD | 97.544% |
| Pro-Dex, Inc. | 54.21 Million USD | 78.12% |
| Pulse Biosciences, Inc. | 60.8 Million USD | 80.493% |
| Predictive Oncology Inc. | 14.41 Million USD | 17.73% |
| Precision Optics Corporation, Inc. | 16.91 Million USD | 29.869% |
| QuidelOrtho Corporation | 8.56 Billion USD | 99.861% |
| Repligen Corporation | 2.82 Billion USD | 99.58% |
| Sanara MedTech Inc. | 73.87 Million USD | 83.944% |
| STAAR Surgical Company | 488.69 Million USD | 97.573% |
| Sharps Technology, Inc. | 11.78 Million USD | -0.608% |
| Utah Medical Products, Inc. | 135.45 Million USD | 91.244% |
| DENTSPLY SIRONA Inc. | 7.37 Billion USD | 99.839% |
| Jin Medical International Ltd. | 32.9 Million USD | 63.952% |